Form 4: Revolution Medicines CEO Sells Shares to Cover Tax Obligations

Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,738 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• Mark A. Goldsmith, the President and CEO of Revolution Medicines, Inc., sold 11,738 shares of common stock on March 17, 2025.
• The sale was executed at a price of $39.0403 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
• Following the transaction, Goldsmith directly owns 441,564 shares of common stock, including 242,900 RSUs.
• Goldsmith also indirectly owns shares through several trusts: Jonathan Goldsmith Revocable Trust (20,424 shares), Rebecca Eve Goldsmith Trust (20,424 shares), and Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust (465,604 shares).

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to an executive's stock sale for tax purposes. It doesn't indicate any significant positive or negative developments for the company.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating transparency and avoiding concerns about insider trading based on non-public information.

Industry Context

Sales of shares by company executives are a common occurrence, often related to tax obligations or diversification strategies. The use of a pre-arranged Rule 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• Executive stock sales are a routine part of corporate governance, with many CEOs and other high-ranking officers periodically selling shares for personal financial planning.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals, which are in a similar industry, often see similar transactions from their executives.
• The use of 10b5-1 plans is a common practice among executives at publicly traded companies to schedule trades in advance and avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Revolution Medicines, RVMD, Mark A. Goldsmith, insider trading, Form 4, share sale, Rule 10b5-1, RSU, restricted stock units, tax withholding